JAMES WALKER GROUP LIMITED

Company number 00176600 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Financial Health Assessment: JAMES WALKER GROUP LIMITED

Financial Health Score: C — Provisional / Guarded

This grade reflects statutory compliance and corporate standing only, not financial performance. The company is active, over a century old, and its filings are currently up to date. However, the supplied data contains no profit and loss, balance sheet, or cash flow figures, so a full financial diagnosis is not possible. The score is therefore provisional: the business appears administratively healthy, but its clinical financial condition (liquidity, solvency, profitability) remains unexamined.


Key Vital Signs

Indicator Reading Interpretation
Corporate status Active The company is registered and not in liquidation, administration, or receivership. This is equivalent to a patient being conscious and responsive.
Filing compliance Accounts and confirmation statement not overdue Statutory “pulse” is stable. Accounts were last made up to 31 March 2026; the confirmation statement was last made up to 14 November 2025. No overdue penalties are indicated.
Company age Incorporated 2 September 1921 Longevity suggests resilience and an established operating history, though age alone does not guarantee current financial strength.
Account category Group The entity files consolidated accounts, indicating it may have subsidiaries. This adds anatomical complexity: the health of the group depends on the health of its parts.
Share capital £6.00 (nominal) Minimal issued share capital. In isolation this is a “thin capitalisation” symptom; it does not by itself indicate distress, but it means the company may rely heavily on retained earnings or external borrowing rather than shareholder equity.
Business activity SIC 70100 — Activities of head offices The company appears to function as a head office or holding entity rather than a direct trading operation. Its financial wellness is therefore likely tied to the performance of underlying group companies.
People with significant control Statement present; no detail supplied A PSC statement exists, but the provided data does not reveal who ultimately owns or controls the company. This is a transparency gap in the medical record.
Website jameswalkergroup.co.uk (crawled, unverified) Online presence noted, but contact and operational details have not been independently verified.

No insolvency proceedings (liquidation, administration, receivership) are recorded.


Diagnosis

Statutorily sound; financially indeterminate.

The company’s “vital signs” from the registry show no immediate symptoms of administrative distress: it is active, filings are current, and there are no formal insolvency proceedings. Its long incorporation history suggests it has survived multiple economic cycles.

However, the absence of published financial figures in the supplied data means the following cannot be assessed:

  • Liquidity: Whether current assets comfortably cover current liabilities (working capital).
  • Solvency: Whether total assets exceed total liabilities and whether the company can meet its debts as they fall due.
  • Profitability: Whether the head office and group generate sustainable earnings.
  • Cash flow: Whether the business generates sufficient cash to operate without distress.

The nominal share capital of £6 and the head-office SIC code suggest this may be a holding or group parent entity. If so, its financial health is likely a reflection of its subsidiaries rather than standalone trading. Without reviewing the full filed group accounts, including the directors’ report and any going concern statement, a definitive clinical diagnosis cannot be made.


Recommendations

  1. Obtain the full filed accounts. Request the complete annual accounts for the year ended 31 March 2026 from Companies House, including the balance sheet, profit and loss account, cash flow statement, and notes. These are the equivalent of blood tests and imaging; they are essential for an accurate diagnosis.

  2. Calculate core liquidity ratios. Once figures are available, assess the current ratio (current assets ÷ current liabilities) and quick ratio to determine whether the company can meet short-term obligations.

  3. Assess solvency and gearing. Review net assets, shareholders’ funds, and any borrowings. A low equity base relative to debt would be a warning sign of financial fragility.

  4. Review the directors’ report. Look for statements on going concern, principal risks, and future outlook. The accounts may contain the company’s own claims about performance and prospects; these should be treated as management assertions until verified.

  5. Verify PSC and ownership details. Confirm who holds significant control or ownership, as this affects governance and decision-making.

  6. Maintain filing discipline. Continue to monitor accounts and confirmation statement deadlines to avoid late-filing penalties, which can be an early symptom of administrative strain.

  7. Consider a group-wide review. Because this is a group entity, examine the financial health of key subsidiaries, not just the parent.


Perspective: Financial Health Diagnostician · Model: nvidia/nemotron-3.5-super-vl:free · Generated 7 November 2026